USPTO Reissues Patent To OSI Replacing Tarceva Composition Of Matter Patent
The US Patent & Trademark Office (USPTO) has granted reissue patent RE41,065 to OSI Pharmaceuticals (OSI) replacing Tarceva’s (erlotinib) composition of matter patent (formerly No.5,747,498). The company had
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.